BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 21175304)

  • 1. NFKBIA deletion in glioblastomas.
    Bredel M; Scholtens DM; Yadav AK; Alvarez AA; Renfrow JJ; Chandler JP; Yu IL; Carro MS; Dai F; Tagge MJ; Ferrarese R; Bredel C; Phillips HS; Lukac PJ; Robe PA; Weyerbrock A; Vogel H; Dubner S; Mobley B; He X; Scheck AC; Sikic BI; Aldape KD; Chakravarti A; Harsh GR
    N Engl J Med; 2011 Feb; 364(7):627-37. PubMed ID: 21175304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres.
    Patanè M; Porrati P; Bottega E; Morosini S; Cantini G; Girgenti V; Rizzo A; Eoli M; Pollo B; Sciacca FL; Pellegatta S; Finocchiaro G
    Mol Cancer; 2013 Dec; 12():160. PubMed ID: 24330732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NFKBIA deletion in glioblastomas.
    Idbaih A; Marie Y; Sanson M
    N Engl J Med; 2011 Jul; 365(3):277; author reply 277-8. PubMed ID: 21774727
    [No Abstract]   [Full Text] [Related]  

  • 4. Alteration in NFKBIA and EGFR in glioblastoma multiforme.
    Komotar RJ; Starke RM; Connolly ES; Sisti MB
    Neurosurgery; 2011 Jun; 68(6):N14-5. PubMed ID: 21778941
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of a NFKBIA polymorphism associated with lower NFKBIA protein levels and poor survival outcomes in patients with glioblastoma multiforme.
    Zhao Z; Zhong X; Wu T; Yang T; Chen G; Xie X; Wei Y; Ye M; Zhou Y; Du Z
    Int J Mol Med; 2014 Nov; 34(5):1233-40. PubMed ID: 25215581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NFKBIA deletion in glioblastomas.
    Takeuchi S; Nawashiro H
    N Engl J Med; 2011 Jul; 365(3):276-7; author reply 277-8. PubMed ID: 21774728
    [No Abstract]   [Full Text] [Related]  

  • 7. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
    Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
    JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history.
    Furukawa M; Soh J; Yamamoto H; Ichimura K; Shien K; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Toyooka S; Miyoshi S
    Acta Med Okayama; 2013; 67(1):19-24. PubMed ID: 23439505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
    Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
    Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of molecular markers in a series of 220 primary glioblastomas.
    Houillier C; Lejeune J; Benouaich-Amiel A; Laigle-Donadey F; Criniere E; Mokhtari K; Thillet J; Delattre JY; Hoang-Xuan K; Sanson M
    Cancer; 2006 May; 106(10):2218-23. PubMed ID: 16568472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
    Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
    N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion and low expression of NFKBIA are associated with poor prognosis in lower-grade glioma patients.
    Kinker GS; Thomas AM; Carvalho VJ; Lima FP; Fujita A
    Sci Rep; 2016 Apr; 6():24160. PubMed ID: 27052952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of the epidermal growth factor receptor gene in glioblastoma: an analysis of the relationship between genotype and phenotype by CISH method.
    Miyanaga T; Hirato J; Nakazato Y
    Neuropathology; 2008 Apr; 28(2):116-26. PubMed ID: 18021194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reverse transcriptase polymerase chain reaction as a reliable method to detect epidermal growth factor receptor exon 2-7 gene deletion in human glioblastomas.
    Worm K; Dabbagh P; Schwechheimer K
    Hum Pathol; 1999 Feb; 30(2):222-7. PubMed ID: 10029453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 16. A prognostic analysis of pediatrics central nervous system small cell tumors: evaluation of EGFR family gene amplification and overexpression.
    Liu W; Zhang S; Zhang L; Cui Q; Wang J; Gui T; Pang Q
    Diagn Pathol; 2014 Jul; 9():132. PubMed ID: 24986561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic implication of alterations in epidermal growth factor receptor and MGMT in glioblastoma].
    Zhang LY; Ge HJ; Wang LM; Zhao LH; Liu L; Zhang DJ; Cai YN; Lu DH; Piao YS
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):186-191. PubMed ID: 30831643
    [No Abstract]   [Full Text] [Related]  

  • 18. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
    Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
    Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
    Aghi M; Gaviani P; Henson JW; Batchelor TT; Louis DN; Barker FG
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8600-5. PubMed ID: 16361543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Liberski PP
    Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.